SLC5A2 and type 2 diabetes mellitus: It may be explained by the epidemic rise in cases with type 2 diabetes or it could as well be associated with the increasing prescription rate of SGLT2 inhibitors that are widely recommended in current guidelines but are known to increase the risk of euglycemic ketoacidosis (40, 41).